about
Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody TherapyCarvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk StratificationA Trial for HER2 Positive Breast Cancer Patients With Metastatic DiseaseTw HER2 Positive Breast Cancer Productivity & Utility StudyTucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerKN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
P1050
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansineAutophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerTargeted therapy for HER2 positive breast cancerPotential of afatinib in the treatment of patients with HER2-positive breast cancerRole of pertuzumab in the treatment of HER2-positive breast cancerRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerHER2-positive breast cancer: available targeted agents and biomarkers for therapy responseProfiling and targeting HER2-positive breast cancer using trastuzumab emtansineCo-Targeting of JNK and HUNK in Resistant HER2-Positive Breast CancerTrastuzumab emtansine for HER2-positive advanced breast cancer.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancert-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer CellsDual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.Whole genome DNA methylation signature of HER2-positive breast cancerThe trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancerTissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.Advances in treating HER2-positive breast cancer: an interview with Sunil Verma.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.Lipid profiles for HER2-positive breast cancer.An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancerThe prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.HER2-positive advanced breast cancer.HER2-positive breast cancer: current and future treatment strategies.HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.Her2-positive breast cancer: herceptin and beyond.Dual HER2-targeted approaches in HER2-positive breast cancer.HER2-positive breast cancer.HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerG1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast CancerEfficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
P921
Q27908387-18B80788-C1C5-4F3E-BDA0-4DD7A5439384Q27908387-224A16DC-054A-4A2A-9D8B-B34C1F489B70Q27908387-33E4573A-1361-40D7-96BB-38CB8147C87EQ27908387-38ECCDE9-32FB-4C36-8BBA-049F0F9FBC1DQ27908387-3DFF293B-3A8E-4870-A5C1-64BBCBDFF3B7Q27908387-5296DBAE-0010-4BBA-8100-C0137F0554FEQ27908387-61B6875B-668B-4D7F-A9A3-43244BE5D7A0Q27908387-62E8E00F-B972-4D1D-80D3-B9AB693E86C8Q27908387-852D60B0-1029-45FF-845A-960FDCF773E1Q27908387-8C5DBD7A-45BA-4C32-8623-8AA02908CB2FQ27908387-A0AC4015-48B3-4FC1-AF9D-151D5DD15FDEQ27908387-ADB29742-BA13-45A7-A5A6-E1625F8BF057Q27908387-C1F66121-3DFE-46B3-A681-7F90B8BA36F3Q27908387-C4E939E9-5557-4347-91C5-55793B945B3DQ27908387-D45BD2B4-3156-4A63-8A5B-64BC6946F8B7Q27908387-E3412104-1F09-4B30-A6FB-443B2EF1BB45Q27908387-F3B92E79-9D8E-4F63-A95C-65049458FA8BQ27908387-F3EAA4A6-1D53-4766-A4C9-D6C351F6043CQ27908387-F6157D28-FA4B-4826-BB40-1F1F10795BE1Q27908387-FBC7AE18-5511-4AB9-AA8F-D3060BA26607Q28371031-CA208F09-3342-4C2C-8FB6-735843848755Q28371034-283CE1D9-A28C-44C7-908A-D15C13C01611Q28371034-613A6FB1-FFBA-4DE8-80E7-26957DFF404EQ28444976-16C76A9A-7591-4204-89D6-F1E1DE2C3F8AQ28444976-36331D78-B30D-4C5C-B5F5-EDB413DA8DE7Q28444976-365F773F-6A8D-44C9-83BF-2EC167C96253Q28444976-5BA6DB41-1112-46AF-AAD4-F8B489943B9CQ28444976-DF640D50-2DFF-4B69-81FC-21C350B7C9F9Q28445019-483CA13D-9631-4E6E-B205-C6761309C1C9Q28445019-7B9BC319-8FB5-412C-848E-BECFF08E4E60Q28445019-A99AECFE-0F58-4683-9D94-31EE9FB864F7Q28445020-8706BE1D-8AD1-4F95-AD73-9DA7F42AA05BQ28445160-531FBA00-EAC4-4F13-A1C7-5B5955148FF9Q29938315-C67AFAF1-02C9-4BE7-B873-8879923CD346
P2175
Q26747729-61665885-4c9a-b988-117b-e27080c7f07dQ26753162-8ab26601-46a2-9b5a-6683-989432a36c82Q26777733-c23f736e-4af3-6650-4ab3-c78433bb1c3dQ26785612-3667410e-44fd-30ee-95b7-3b2487ca36c8Q26830496-595f3022-46c4-ef6c-fa7a-cc0c99bbdcdeQ26999050-63b7e85f-41d8-615f-3082-dd77b1221ceeQ27002386-2543504b-40d9-b9f3-e6a9-3bc4c7a00308Q27003258-ef3c639b-492d-8798-b2c7-7f2efc1265feQ27015031-74a6af13-4797-06f7-e4b4-55c5f2790a3eQ27015048-c0add28a-4bab-eb1d-7556-b8bbf02ec320Q27314840-cbab877c-472e-9767-4b85-7ef362bbd8ecQ27851917-6f52eb0d-4afa-f3bd-8393-f8ac110b25a3Q27853001-cb1bf2ab-48de-0aa6-99ad-0c902b9cd373Q27853194-02057848-4fe7-205c-050f-8544cf692ebfQ28085413-d541e3b0-4c36-f51a-c28d-d0383af1d4d3Q28545954-17961dce-45de-1798-8cdc-a8c69cd6e392Q34009045-22a93afc-4bba-a8b8-8ae1-5f7f9343beccQ34118863-4c35e292-400f-e8bc-13bb-b1e4a2618006Q34183426-4b6c1159-4f00-cb11-896a-1ca5c6ca1008Q34305948-3ff4b52f-4223-ad23-c0e5-d96a510144b1Q34323926-adb1cfb4-4c9e-4694-bf0b-61240712dc79Q34499609-6a6a95d7-42f5-369a-eeac-277550a53c8fQ34571685-81e03656-4ac8-e94e-4815-041a1f7e3a68Q34664129-97cee82e-4f8c-6cc9-d493-e3de6ecfb2beQ34713726-eebf0a17-46a1-c65a-9adf-0d51da98c384Q34763921-65121a62-42e4-940f-f4df-7dca4a665624Q34776985-457c2ce0-44a5-e715-fc3b-27a28db3038aQ34996222-d6a6f29a-4020-5a9a-8235-741548c979e7Q36826418-2c9f37a8-44df-21ae-8391-296d9507202cQ36839672-06bcf526-4c17-5295-5ba5-752813f09f13Q37172068-5fa77627-4598-6b7f-8c89-3e0c18a8887eQ37330891-59799ba3-48b3-6a7f-ee78-723f84f97f6fQ37940203-d2a37e6c-47b4-5871-d252-9a50bd2b1b6fQ39034850-a7da59d5-4d6d-d751-5ba9-9e7a60c3191bQ39620638-57026f4c-442a-b98b-ff50-8131b0bb153fQ53074363-9177a359-421e-6cdd-4039-0b5af792a916Q62022868-8a81f9ae-48d1-f5fc-0589-1136142927e2Q63400450-23F08F94-0A28-45A3-8675-13B78DCC9952Q63571525-80F80A94-EF21-436E-9DE1-7B26336F855CQ96143320-E68B3EBB-C4FC-45C5-B737-2D75F83499C4
P921
description
Human disease
@en
Krankheit
@de
مرض يصيب الإنسان
@ar
name
Her2-receptor positive breast cancer
@en
cancer du sein HER2
@fr
type
label
Her2-receptor positive breast cancer
@en
cancer du sein HER2
@fr
altLabel
ERBB2 Overexpressing Subtype of Breast Carcinoma
@en
HER2 Overexpressing Breast Carcinoma
@en
HER2 Overexpressing Subtype of Breast Carcinoma
@en
HER2 Positive Breast Cancer
@en
HER2 Positive Breast Carcinoma
@en
HER2+ breast cancer
@en
Her2-receptor positive breast cancer
@en
prefLabel
Her2-receptor positive breast cancer
@en
cancer du sein HER2
@fr
P279
P1748
P2892
P31
P5270
MONDO:0006244
P699
DOID:0060079